Global Cancer Diagnostics Market Report and Forecast 2024-2032
Description
Global Cancer Diagnostics Market Report and Forecast 2024-2032
Global Cancer Diagnostics Market Report and Forecast 2024-2032
The global cancer diagnostics market size was valued at USD 106.24 billion in 2023. It is expected to grow at a CAGR of 9.12% during the forecast period of 2024-2032, driven by the government initiatives and funding for cancer research across the globe. The market is experiencing robust growth and is expected to reach USD 231.93 billion by 2032.
Global Cancer Diagnostics Market Analysis
The global cancer diagnostics market is experiencing significant growth, driven by the rising incidence of cancer worldwide, advancements in diagnostic technologies, and an increasing emphasis on early detection to improve treatment outcomes. This analysis provides an overview of the current state of the market, key drivers, challenges, and emerging trends, offering insights into the future trajectory of cancer diagnostics.
Global Cancer Diagnostics Market Drivers
Several factors are propelling the growth of the cancer diagnostics market. Firstly, the global increase in cancer prevalence necessitates robust diagnostic solutions for early detection and management. Secondly, technological advancements in diagnostics, such as next-generation sequencing (NGS), are enhancing the accuracy and efficiency of cancer detection. Furthermore, government initiatives and funding for cancer research are supporting the development and adoption of advanced diagnostic methods. Lastly, the growing preference for personalized medicine is driving demand for precise diagnostic tools that can guide tailored treatment approaches.
Market Challenges
Despite the growth, the market faces challenges, including the high cost of advanced diagnostic tests, which may limit accessibility in low- and middle-income countries. Additionally, the complexity of regulatory approvals for new diagnostic technologies can delay their market entry and adoption. There's also a critical need for skilled professionals to operate advanced diagnostic equipment and interpret results accurately, posing a barrier to the widespread implementation of new technologies.
Global Cancer Diagnostics Market Outlook
The global cancer diagnostics market is poised for continued growth, with an increasing emphasis on early detection, minimally invasive diagnostic methods, and integration of digital technologies to improve diagnostic accuracy and patient outcomes. As research progresses and awareness increases, the market is expected to witness the introduction of more innovative diagnostic solutions, catering to the evolving needs of healthcare providers and patients alike. Collaboration among research institutions, industry players, and regulatory bodies will be key to overcoming existing challenges and fully realizing the potential of advanced cancer diagnostics in improving global health outcomes.
Global Cancer Diagnostics Market Trends
The global cancer diagnostics market is witnessing significant growth, driven by technological advancements, increasing prevalence of cancer worldwide, and a growing emphasis on early detection and personalized treatment. The following trends are shaping the future of cancer diagnostics:
1. Technological Innovations
Rapid advancements in diagnostic technologies, including next-generation sequencing (NGS), liquid biopsy, and artificial intelligence (AI)-enhanced imaging, are transforming cancer diagnostics. These innovations enable more precise, non-invasive, and early detection of cancer, facilitating personalized treatment plans and improving patient outcomes.
2. Liquid Biopsy Emergence
Liquid biopsy is gaining traction as a revolutionary approach for cancer detection and monitoring. This minimally invasive technique analyzes circulating tumor DNA (ctDNA) in blood samples to detect cancer at early stages, monitor treatment response, and identify molecular changes without the need for traditional biopsy procedures. Its convenience and efficiency are driving its adoption in clinical settings.
3. Increased Focus on Personalized Medicine
The shift towards personalized or precision medicine is profoundly impacting the cancer diagnostics market. Personalized treatment plans based on genetics, biomarker, and other molecular data are becoming the norm, necessitating advanced diagnostics to identify specific cancer types and their genetic mutations. This approach ensures more targeted and effective treatments, driving demand for sophisticated diagnostic tests.
4. Rising Cancer Prevalence
The global increase in cancer cases is a primary driver for the expansion of the cancer diagnostics market. Aging populations, lifestyle factors, and environmental influences contribute to rising cancer rates, highlighting the need for advanced diagnostic solutions to manage the growing burden of this disease.
5. Integration of Artificial Intelligence
AI is playing a crucial role in enhancing the accuracy, speed, and efficiency of cancer diagnostics. AI algorithms are being used to interpret complex imaging data, identify patterns not visible to the human eye, and predict disease progression. This integration improves diagnostic precision and facilitating faster decision-making in treatment planning.
6. Expanding Applications of Genomic Testing
Genomic testing is at the forefront of identifying genetic predispositions to various cancers, understanding tumor genetics, and selecting targeted therapies. The declining cost of genomic sequencing and the growing understanding of genetic markers in cancer are expanding the use of genomic testing in oncology.
7. Regulatory and Reimbursement Landscape Evolution
The regulatory and reimbursement environment is evolving to keep pace with rapid technological advancements in cancer diagnostics. Governments and insurance providers are increasingly recognizing the value of early and accurate cancer detection, leading to more supportive policies and reimbursement frameworks for innovative diagnostic tests.
8. Collaboration and Mergers
Strategic collaborations and mergers between diagnostic companies, pharmaceutical firms, and technology providers are becoming common. These partnerships aim to combine expertise in different areas, such as biomarker discovery, diagnostic technology development, and AI, to accelerate the development and commercialization of advanced cancer diagnostic solutions.
9. Emerging Markets Growth
The cancer diagnostics market is expanding rapidly in emerging economies, driven by increasing healthcare spending, growing awareness of early cancer detection, and improvements in healthcare infrastructure. This expansion presents significant opportunities for market growth and innovation.
10. Patient Empowerment and Awareness
There is a growing emphasis on patient empowerment and awareness regarding the importance of early cancer detection. Educational initiatives and screening programs are increasing public knowledge about cancer symptoms and the availability of diagnostic tests, encouraging people to seek early diagnosis and treatment.
Global Cancer Diagnostics Market Segmentation
Market Breakup by Product Type
- Consumables
- Instruments
Market Breakup by Technology
- In-Vitro Diagnostics
- Imaging
- Biopsy Instruments
- Others
Market Breakup by Application
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Liver Cancer
- Others
Market Breakup by End User
- Hospitals and Clinics
- Diagnostic Centers
- Research Institutes
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Cancer Diagnostics Market Competitive Landscape
The competitive landscape of the market is defined by the activities of leading companies. These key players are engaged in a variety of strategic initiatives including mergers and acquisitions, research and development efforts, product launches, and collaborations to strengthen their market positions and expand their product portfolios. Major companies in the market are as follows:
- Thermo Fisher Scientific
- PerkinElmer
- Stemcell Technologies
- Merck
- Bio-Rad Laboratories
- Agilent Technologies
- Promega
- Bio-Techne
- Cell Biolabs
- What is the current and future performance of the global cancer diagnostics market?
- What are the factors that influence the growth, decline, and potential of the market?
- What strategies are key players in the market adopting to strengthen their market positions?
- How do different end-user segments contribute to the growth of the global cancer diagnostics market?
- How do various cancer types contribute to the dynamics and growth of the global cancer diagnostics market?
- How does each technology segment contribute to the growth of the global cancer diagnostics market?
- How do the consumables and instruments segments influence the growth of the global cancer diagnostics market?
- How is the market organized in terms of competition?
- What are the main players/companies in the market?
- The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global cancer diagnostics market from 2017-2032.
- The research report provides the latest information on the market drivers, challenges, and opportunities in the global cancer diagnostics market.
- The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the global cancer diagnostics industry and its attractiveness.
- The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
Table of Contents
140 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Cancer Diagnostics Market Overview
- 3.1 Global Cancer Diagnostics Market Historical Value (2017-2023)
- 3.2 Global Cancer Diagnostics Market Forecast Value (2024-2032)
- 4 Global Cancer Diagnostics Market Landscape*
- 4.1 Global Cancer Diagnostics: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Cancer Diagnostics: Product Type Landscape
- 4.2.1 Analysis by Product Type
- 4.2.2 Analysis by Technology
- 4.2.3 Analysis by Application
- 5 Global Cancer Diagnostics Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Cancer Diagnostics Market Segmentation (2017-2032)
- 6.1 Global Cancer Diagnostics Market (2017-2032) by Product Type
- 6.1.1 Market Overview
- 6.1.2 Consumables
- 6.1.3 Instruments
- 6.2 Global Cancer Diagnostics Market (2017-2032) by Technology
- 6.2.1 Market Overview
- 6.2.2 In-Vitro Diagnostics
- 6.2.3 Imaging
- 6.2.4 Biopsy Instruments
- 6.2.5 Others
- 6.3 Global Cancer Diagnostics Market (2017-2032) by Application
- 6.3.1 Market Overview
- 6.3.2 Lung Cancer
- 6.3.3 Breast Cancer
- 6.3.4 Colorectal Cancer
- 6.3.5 Prostate Cancer
- 6.3.6 Liver Cancer
- 6.3.7 Others
- 6.4 Global Cancer Diagnostics Market (2017-2032) by End User
- 6.4.1 Market Overview
- 6.4.2 Hospitals & Clinics
- 6.4.3 Diagnostic Centers
- 6.4.4 Research Institutes
- 6.4.5 Others
- 6.5 Global Cancer Diagnostics Market (2017-2032) by Region
- 6.5.1 Market Overview
- 6.5.2 North America
- 6.5.3 Europe
- 6.5.4 Asia Pacific
- 6.5.5 Latin America
- 6.5.6 Middle East and Africa
- 7 North America Cancer Diagnostics Market (2017-2032)
- 7.1 North America Cancer Diagnostics Market (2017-2032) by Product Type
- 7.1.1 Market Overview
- 7.1.2 Consumables
- 7.1.3 Instruments
- 7.2 North America Cancer Diagnostics Market (2017-2032) by Application
- 7.2.1 Market Overview
- 7.2.2 Lung Cancer
- 7.2.3 Breast Cancer
- 7.2.4 Colorectal Cancer
- 7.2.5 Prostate Cancer
- 7.2.6 Liver Cancer
- 7.2.7 Others
- 7.3 North America Cancer Diagnostics Market (2017-2032) by Country
- 7.3.1 United States of America
- 7.3.2 Canada
- 8 Europe Cancer Diagnostics Market (2017-2032)
- 8.1 Europe Cancer Diagnostics Market (2017-2032) by Product Type
- 8.1.1 Market Overview
- 8.1.2 Consumables
- 8.1.3 Instruments
- 8.2 Europe Cancer Diagnostics Market (2017-2032) by Application
- 8.2.1 Market Overview
- 8.2.2 Lung Cancer
- 8.2.3 Breast Cancer
- 8.2.4 Colorectal Cancer
- 8.2.5 Prostate Cancer
- 8.2.6 Liver Cancer
- 8.2.7 Others
- 8.3 Europe Cancer Diagnostics Market (2017-2032) by Country
- 8.3.1 United Kingdom
- 8.3.2 Germany
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Others
- 9 Asia Pacific Cancer Diagnostics Market (2017-2032)
- 9.1 Asia Pacific Cancer Diagnostics Market (2017-2032) by Product Type
- 9.1.1 Market Overview
- 9.1.2 Consumables
- 9.1.3 Instruments
- 9.2 Asia Pacific Cancer Diagnostics Market (2017-2032) by Application
- 9.2.1 Market Overview
- 9.2.2 Lung Cancer
- 9.2.3 Breast Cancer
- 9.2.4 Colorectal Cancer
- 9.2.5 Prostate Cancer
- 9.2.6 Liver Cancer
- 9.2.7 Others
- 9.3 Asia Pacific Cancer Diagnostics Market (2017-2032) by Country
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 ASEAN
- 9.3.5 Australia
- 9.3.6 Others
- 10 Latin America Cancer Diagnostics Market (2017-2032)
- 10.1 Latin America Cancer Diagnostics Market (2017-2032) by Product Type
- 10.1.1 Market Overview
- 10.1.2 Consumables
- 10.1.3 Instruments
- 10.2 Latin America Cancer Diagnostics Market (2017-2032) by Application
- 10.2.1 Market Overview
- 10.2.2 Lung Cancer
- 10.2.3 Breast Cancer
- 10.2.4 Colorectal Cancer
- 10.2.5 Prostate Cancer
- 10.2.6 Liver Cancer
- 10.2.7 Others
- 10.3 Latin America Cancer Diagnostics Market (2017-2032) by Country
- 10.3.1 Brazil
- 10.3.2 Argentina
- 10.3.3 Mexico
- 10.3.4 Others
- 11 Middle East and Africa Cancer Diagnostics Market (2017-2032)
- 11.1 Middle East and Africa Cancer Diagnostics Market (2017-2032) by Product Type
- 11.1.1 Market Overview
- 11.1.2 Consumables
- 11.1.3 Instruments
- 11.2 Middle East and Africa Cancer Diagnostics Market (2017-2032) by Application
- 11.2.1 Market Overview
- 11.2.2 Lung Cancer
- 11.2.3 Breast Cancer
- 11.2.4 Colorectal Cancer
- 11.2.5 Prostate Cancer
- 11.2.6 Liver Cancer
- 11.2.7 Others
- 11.3 Middle East and Africa Cancer Diagnostics Market (2017-2032) by Country
- 11.3.1 Saudi Arabia
- 11.3.2 United Arab Emirates
- 11.3.3 Nigeria
- 11.3.4 South Africa
- 11.3.5 Others
- 12 Regulatory Framework
- 12.1 Regulatory Overview
- 12.1.1 US FDA
- 12.1.2 EU EMA
- 12.1.3 INDIA CDSCO
- 12.1.4 JAPAN PMDA
- 12.1.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Grants Analysis
- 14.1 Analysis by Year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Application
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by Departments
- 14.7 Analysis by Recipient Organization
- 15 Funding and Investment Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Type of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 Abbott Laboratories
- 17.1.1 Financial Analysis
- 17.1.2 Product Type Portfolio
- 17.1.3 Demographic Reach and Achievements
- 17.1.4 Mergers and Acquisitions
- 17.1.5 Certifications
- 17.2 Thermo Fisher Scientific
- 17.2.1 Financial Analysis
- 17.2.2 Product Type Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisitions
- 17.2.5 Certifications
- 17.3 Illumina Inc.
- 17.3.1 Financial Analysis
- 17.3.2 Product Type Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisitions
- 17.3.5 Certifications
- 17.4 QIAGEN
- 17.4.1 Financial Analysis
- 17.4.2 Product Type Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisitions
- 17.4.5 Certifications
- 17.5 F. Hoffmann La Roche Ltd.
- 17.5.1 Financial Analysis
- 17.5.2 Product Type Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisitions
- 17.5.5 Certifications
- 17.6 Becton, Dickinson, and Company
- 17.6.1 Financial Analysis
- 17.6.2 Product Type Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisitions
- 17.6.5 Certifications
- 17.7 Koninklijke Philips N.V.
- 17.7.1 Financial Analysis
- 17.7.2 Product Type Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisitions
- 17.7.5 Certifications
- 17.8 Siemens Healthineers
- 17.8.1 Financial Analysis
- 17.8.2 Product Type Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisitions
- 17.8.5 Certifications
- 17.9 Hologic Inc.
- 17.9.1 Financial Analysis
- 17.9.2 Product Type Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisitions
- 17.9.5 Certifications
- 17.10 GE Healthcare
- 17.10.1 Financial Analysis
- 17.10.2 Product Type Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisitions
- 17.10.5 Certifications
- 17.11 Agilent Technologies Inc.
- 17.11.1 Financial Analysis
- 17.11.2 Product Type Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisitions
- 17.11.5 Certifications
- 17.12 Quest Diagnostics
- 17.12.1 Financial Analysis
- 17.12.2 Product Type Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Mergers and Acquisitions
- 17.12.5 Certifications
- 17.13 Biomerieux SA
- 17.13.1 Financial Analysis
- 17.13.2 Product Type Portfolio
- 17.13.3 Demographic Reach and Achievements
- 17.13.4 Mergers and Acquisitions
- 17.13.5 Certifications
- 17.14 Myriad Genetics
- 17.14.1 Financial Analysis
- 17.14.2 Product Type Portfolio
- 17.14.3 Demographic Reach and Achievements
- 17.14.4 Mergers and Acquisitions
- 17.14.5 Certifications
- List not exhaustive!
- 18 Global Cancer Diagnostics Market – Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
- 21.1 Government Funded
- 21.2 Private Insurance
- 21.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.



